SNTA-liking chart here and recent News Synta Pharmaceuticals advances ganetespib into Phase 3 extension of AML LI-1 Synta Pharmaceuticals announced the advancement of ganetespib into the Phase 3 extension of the AML LI-1 trial. http://www.theflyonthewall.com/permalinks/entry.php/SNTAid2041209/SNTA-Synta-Pharmaceuticals-data-positive--says-JMP-Securities stockcharts.com/c-sc/sc?s=SNTA&p=D&b=5&g=0&i=0&r=1406137619677